Presentations by Program

Potent activity of sulbactam-durlobactam against pan-drug resistant Acinetobacter baumannii-calcoaceticus complex (ABC) isolates from a recent 5-year surveillance study (2016-2020)

Sarah McLeod, Alita Miller, Meredith Hackel, Daniel Sahm (ASM Microbe, 2022)

In vitro activity of sulbactam-durlobactam against recent clinical Acinetobacter baumannii-calcoaceticus complex isolates from the United States

Adam Shapiro, Sarah McLeod, Samir Moussa, Meredith Hackel, Alita Miller (ASM Microbe, 2022)

In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii clinical isolates collected in 2020 from China

Sarah McLeod, Meredith Hackel, Alita Miller (ASM Microbe, 2022)

Sulbactam-durlobactam is associated with lower mortality from index Acinetobacter infections in the ATTACK phase 3 registrational trial

David Altarac, Adam Shapiro , Khurram Rana, Drew Lewis (ATS, 2022)

In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates from a five-year surveillance program (2016 – 2020)

Meredith Hackel, Sarah McLeod, Alita Miller and Daniel Sahm (ECCMID, 2022)

Safety profile of sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections from the global, randomized, active-controlled phase 3 trial (ATTACK)

Drew Lewis, Khurram Rana, Melissa Steidler, Gabrielle Poirier and David Altarac (ECCMID, 2022)

Sulbactam-durlobactam (SUL-DUR) in vitro dose response studies with and without imipenem or meropenem against carbapenemase-producing Acinetobacter baumannii utilizing the hollow-fiber infection model

John O'Donnell, Angela Tanudra, Sarah McLeod, Alita Miller and Ruben Tommasi (ECCMID, 2022)

Characterization of co-infecting Gram-negative pathogens isolated in addition to Acinetobacter baumannii-calcoaceticus complex (ABC) at baseline from patients enrolled in the ATTACK phase 3 trial

Alita Miller, Sarah McLeod, Daria Chabas, Gabrielle Poirier, and David Altarac (ECCMID, 2022)

Efficacy and safety of sulbactam-durlobactam (SUL-DUR) therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections in the open label Part B of the ATTACK phase 3 trial

Khurram Rana, David Altarac, Robin Isaacs, Subasree Srinivasan, Sarah McLeod, Gabrielle Poirier, Andrew Shorr and Keith Kaye (ECCMID, 2022)

Characterization of Acinetobacter baumannii-calcoaceticus complex (ABC) pathogens isolated at baseline from patients enrolled in the ATTACK phase 3 trial

Alita Miller, Sarah McLeod, Daria Chabas, Gabrielle Poirier and David Altarac (ECCMID, 2022)